MGNX: Major cash infusions and pipeline progress set stage for innovation and clinical milestones – TradingView
Significant non-dilutive capital from royalty and manufacturing deals extends runway through 2028, enabling robust investment in a diversified pipeline. Key clinical updates are expected for lorigerlimab and next-gen ADCs, with a focus on innovation and strategic collaborations.Based on MacroGenics, Inc. [MGNX] Stifel 2026 Targeted Oncology Virtual Forum Audio Transcript — – See more –


You must be logged in to post a comment.